Logos Global Management’s Enliven Therapeutics ELVN Stock Holding History

Logos Global Management’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.6M	Sell	465,000 -75,000	-14%	-$3.18M	1.02%	32
2026 Q1	$21.2M	Buy	540,000 +200,000	+59%	+$5.54M	1.06%	31
2025 Q4	$5.24M	Hold	340,000	–	–	0.32%	52
2025 Q3	$6.96M	Sell	340,000 -10,000	-3%	-$202K	0.62%	42
2025 Q2	$7.02M	Buy	350,000 +110,000	+46%	+$2.08M	0.78%	38
2025 Q1	$4.72M	Buy	240,000 +100,000	+71%	+$2.15M	0.84%	26
2024 Q4	$3.15M	Sell	140,000 -355,000	-72%	-$9.2M	0.37%	43
2024 Q3	$12.6M	Sell	495,000 -100,000	-17%	-$2.32M	1.36%	25
2024 Q2	$13.9M	Sell	595,000 -979,220	-62%	-$20.6M	1.12%	29
2024 Q1	$26.4M	Buy	1,574,220 +1,267,144	+413%	+$19.4M	2.14%	16
2023 Q4	$4.25M	Hold	307,076	–	–	0.4%	45
2023 Q3	$4.19M	Hold	307,076	–	–	0.56%	42
2023 Q2	$6.27M	Sell	307,076 -94,153	-23%	-$1.9M	0.85%	35
2023 Q1	$8.79M	Buy	+401,229	New	+$8.16M	1.26%	30

Other funds holding ELVN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Logos Global Management's ELVN Position: Q2 2026 in Review

Logos Global Management reduced its Enliven Therapeutics (ELVN) stake by 14% in Q2 2026, selling an estimated $3.18M and leaving 465,000 shares worth $23.6M. The position accounts for 1.02% of the portfolio, ranked #32.

Logos Global Management first reported a position in ELVN in Q1 2023 and has held it in 14 quarters since. The position peaked at $26.4M in Q1 2024. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

Logos Global Management held 465,000 shares of Enliven Therapeutics worth $23.6M as of Q2 2026.
Logos Global Management sold 75,000 Enliven Therapeutics shares in Q2 2026, an estimated $3.18M.
Enliven Therapeutics made up 1.02% of Logos Global Management's portfolio in Q2 2026, its #32 holding.
Logos Global Management first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 14 quarters since.
Logos Global Management's Enliven Therapeutics position peaked at $26.4M in Q1 2024.
210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.